31246-66-9

Basic information

• Product Name: cis,cis,trans-Diamminedichlorodihydroxoplatinum
• Synonyms: Oxoplatinum; Platinum,diamminedichlorodihydroxy-, stereoisomer (8CI); Oxo-Pt; Oxoplatin
• CAS NO: 31246-66-9
• Molecular Formula: Cl₂H₈N₂O₂Pt
• Molecular Weight: 334.0657
• Mol File: 31246-66-9.mol
• Article Data: 67

Chemical Properties

• CAS DataBase Reference: cis,cis,trans-Diamminedichlorodihydroxoplatinum(CAS DataBase Reference)
• NIST Chemistry Reference: cis,cis,trans-Diamminedichlorodihydroxoplatinum(31246-66-9)
• EPA Substance Registry System: cis,cis,trans-Diamminedichlorodihydroxoplatinum(31246-66-9)

Safety Data

• Hazardous Substances Data: 31246-66-9(Hazardous Substances Data)

Upstream product

• 26035-31-4 cisplatine 
• 7722-84-1 dihydrogen peroxide 
• 15663-27-1 cisplatin 
• 7732-18-5 water 
• 26035-31-4 transplatin 
• 7722-64-7 potassium permanganate 

Downstream Products

• 16893-05-3 cis-diaammineplatinum(IV) tetrachloride 
• 15663-27-1 cisplatin 

Relevant articles and documents

High-activity Pt complex as well as preparation method and application thereof

The invention discloses a high-activity Pt (IV) complex, and belongs to the technical field of anticancer chemical drugs. The complex is represented by the general formula (1) or the general formula (2). General formula (1) (2) The invention introduces 6 - chloro -3 - methylbenzofuran -2 - formic acid or 5 -chloro -3 - methylbenzofuran -2 - formic acid into the platinum (IV) complex to significantly enhance the cytotoxicity of the platinum (IV) complex to cancer cells.

Tetravalent platinum complex containing posaconazole Preparation method and application thereof

The invention provides a tetravalent platinum complex containing posaconazole, a preparation method and application thereof, and the structure is shown in the formula I. The tetravalent platinum complex has obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549, colon cancer HCT116, breast cancer MDA-MB - 231 and cis-platinum drug-resistant lung adenocarcinoma, and the antitumor activity of the partial compound is obviously better than that of cisplatin. In addition, the complex has a remarkable inhibitory activity on common pathogenic fungi, shows significant inhibitory activity on posaconazole drug-resistant candida albicans, and can be used as a new drug for anti-tumor and antifungal candidate drugs.

Tetravalent platinum anticancer complex based on cis-platinum derivative containing ursodic acid ligand and preparation method and application thereof

The invention belongs to the field of pharmaceutical chemistry, and particularly relates to a tetravalent platinum anticancer complex based on cis-platinum-derived ursodic acid ligand and a preparation method and application thereof. Pt (IV) Complex containing the ursolic acid ligand disclosed by the invention adopts cisplatin as a basic mother nucleus, the ursolic acid derivative ligand is introduced at one end in the axial direction, Cl or - OH groups are introduced at the other end. The preparation of the series Pt (IV) complex is cheap and easily available, the method is simple and feasible, the operation is easy, and the method is suitable for large-scale production. In-vitro experiments show Pt (IV) complexes US-CIS-CL and US-CIS-OH show high anticancer activity, superior to cisplatin, and have good anticancer activity.